LT3525583T - Anti-c1s antikūnai ir jų naudojimo būdai - Google Patents

Anti-c1s antikūnai ir jų naudojimo būdai

Info

Publication number
LT3525583T
LT3525583T LTEPPCT/US2017/056349T LTUS2017056349T LT3525583T LT 3525583 T LT3525583 T LT 3525583T LT US2017056349 T LTUS2017056349 T LT US2017056349T LT 3525583 T LT3525583 T LT 3525583T
Authority
LT
Lithuania
Prior art keywords
antibodies
methods
Prior art date
Application number
LTEPPCT/US2017/056349T
Other languages
English (en)
Lithuanian (lt)
Inventor
Sandip PANICKER
Graham Parry
Nancy Stagliano
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of LT3525583T publication Critical patent/LT3525583T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
LTEPPCT/US2017/056349T 2016-10-12 2017-10-12 Anti-c1s antikūnai ir jų naudojimo būdai LT3525583T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662407390P 2016-10-12 2016-10-12
PCT/US2017/056349 WO2018071676A1 (en) 2016-10-12 2017-10-12 Anti-c1s antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
LT3525583T true LT3525583T (lt) 2025-11-10

Family

ID=61906346

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2017/056349T LT3525583T (lt) 2016-10-12 2017-10-12 Anti-c1s antikūnai ir jų naudojimo būdai

Country Status (32)

Country Link
US (2) US20200048332A1 (OSRAM)
EP (2) EP4652926A2 (OSRAM)
JP (3) JP7069138B2 (OSRAM)
KR (3) KR102638884B1 (OSRAM)
CN (2) CN116554320A (OSRAM)
AR (1) AR110677A1 (OSRAM)
AU (3) AU2017341766A1 (OSRAM)
BR (1) BR112019007309A2 (OSRAM)
CA (1) CA3040253A1 (OSRAM)
CL (1) CL2019000975A1 (OSRAM)
CO (1) CO2019004741A2 (OSRAM)
CR (1) CR20190223A (OSRAM)
DK (1) DK3525583T3 (OSRAM)
DO (1) DOP2019000085A (OSRAM)
EA (1) EA201990884A1 (OSRAM)
EC (1) ECSP19033211A (OSRAM)
ES (1) ES3049257T3 (OSRAM)
FI (1) FI3525583T3 (OSRAM)
HR (1) HRP20251304T1 (OSRAM)
IL (2) IL308156A (OSRAM)
LT (1) LT3525583T (OSRAM)
MX (2) MX2019004259A (OSRAM)
MY (1) MY198182A (OSRAM)
PE (1) PE20191031A1 (OSRAM)
PH (1) PH12019500789A1 (OSRAM)
PT (1) PT3525583T (OSRAM)
RS (1) RS67326B1 (OSRAM)
SG (1) SG11201903012RA (OSRAM)
TN (1) TN2019000109A1 (OSRAM)
TW (3) TWI846007B (OSRAM)
WO (1) WO2018071676A1 (OSRAM)
ZA (1) ZA201902247B (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3722320A3 (en) 2012-10-25 2020-12-30 Bioverativ USA Inc. Anti-complement c1s antibodies and uses thereof
PT2914291T (pt) 2012-11-02 2022-05-05 Bioverativ Usa Inc Anticorpos anti-complemento c1s e suas utilizações
HRP20230093T1 (hr) 2015-04-06 2023-03-31 Bioverativ Usa Inc. Humanizirana anti-c1s protutijela i postupci njihove primjene
CN116554320A (zh) 2016-10-12 2023-08-08 美国比奥维拉迪维股份有限公司 抗C1s抗体及其使用方法
WO2019098212A1 (en) 2017-11-14 2019-05-23 Chugai Seiyaku Kabushiki Kaisha Anti-c1s antibodies and methods of use
JP2022532282A (ja) 2019-05-15 2022-07-14 中外製薬株式会社 抗原結合分子、薬学的組成物、および方法
AU2021261257A1 (en) * 2020-04-20 2022-12-22 Genzyme Corporation Humanized anti-complement factor Bb antibodies and uses thereof
JP2023522907A (ja) * 2020-04-22 2023-06-01 ケモマブ リミテッド 抗ｃｃｌ２４抗体を使用する処置方法
EP4149486A1 (en) * 2020-05-11 2023-03-22 Genentech, Inc. Complement component c1s inhibitors for treating a neurological disease, and related compositions, systems and methods of using same
CA3187866A1 (en) * 2020-08-06 2022-02-10 Jaime Morales ARIAS Inflammatory cytokines and fatigue in subject with a complement mediated disease
CN117769434A (zh) 2021-05-20 2024-03-26 黛安瑟斯医疗运营公司 与C1s结合的抗体和其用途
US11958899B2 (en) 2021-07-13 2024-04-16 Mabwell Therapeutics Inc. Anti-C1s antibodies and uses thereof
IL317666A (en) 2022-06-15 2025-02-01 Bioverativ Usa Inc Anti-complement formulation for C1S antibody
AU2023286689A1 (en) 2022-06-24 2025-02-06 Bioverativ Usa Inc. Methods for treating complement-mediated diseases
EP4622670A1 (en) 2022-11-21 2025-10-01 Dianthus Therapeutics OpCo, Inc. Antibodies that bind to c1s and uses thereof
TW202500749A (zh) 2023-03-16 2025-01-01 美商健臻公司 乾性老年黃斑部退化之治療

Family Cites Families (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS60192263A (ja) 1984-03-13 1985-09-30 Teijin Ltd 免疫複合体測定用標準物質及びそれを用いた免疫複合体の測定法
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
CA1276103C (en) 1984-10-02 1990-11-13 Fumiaki Taguchi Substance-conjugated complement component c1q
JPS61271455A (ja) 1985-05-28 1986-12-01 Olympus Optical Co Ltd 免疫学的分析方法
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0318554B2 (en) 1987-05-21 2005-01-12 Micromet AG Targeted multifunctional proteins
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ES2197145T3 (es) 1991-08-20 2004-01-01 The Government Of The Usa As Represented By The Secretary Of The Deptm. Of Health And Human Services Transferencia de genes mediada por adenovirus al gastrointestinal.
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
JPH08503855A (ja) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
AU687829B2 (en) 1993-06-24 1998-03-05 Advec, Inc. Adenovirus vectors for gene therapy
DE69429816T2 (de) 1993-09-01 2002-09-19 Stichting Sanquin Bloedvoorziening, Amsterdam C1-Esterasehemmer zur Verringerung von Myokardschäden bei akutem Herzinfarkt
HU223733B1 (hu) 1993-10-25 2004-12-28 Canji, Inc. Rekombináns adenovírus vektor és eljárás alkalmazására
ES2178101T3 (es) 1994-12-09 2002-12-16 Imp College Innovations Ltd Genes de virulencia en la region vgc2 de salmonella.
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
GB9621680D0 (en) 1996-10-17 1996-12-11 Oxford Biomedica Ltd Lentiviral vectors
AU725143B2 (en) 1996-10-17 2000-10-05 Oxford Biomedica (Uk) Limited Retroviral vectors
GB9622500D0 (en) 1996-10-29 1997-01-08 Oxford Biomedica Ltd Therapeutic gene
US7083786B2 (en) 1997-04-03 2006-08-01 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
CA2321140C (en) 1998-02-20 2015-04-07 Tanox, Inc. Inhibitors of complement activation
US6103526A (en) 1998-10-08 2000-08-15 Protein Sciences Corporation Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using
CA2360233A1 (en) 1999-02-09 2000-08-17 3-Dimensional Pharmaceuticals, Inc. Methods of treating c1s-mediated diseases and conditions, and compounds and compositions therefor
AU4369000A (en) 1999-04-26 2000-11-10 Duke University Inhibition of complement action
AU6929100A (en) 1999-08-23 2001-03-19 Biocrystal Limited Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis
JP2003523233A (ja) 2000-01-19 2003-08-05 バイオトランスプラント，インコーポレイテッド ブタ内因性レトロウイルスの伝達を欠くブタおよびその用途
EP1252184B1 (en) 2000-01-31 2008-01-02 Pharming Intellectual Property B.V. Human c1 inhibitor produced in the milk of transgenic mammals
AU2001249410A1 (en) 2000-03-23 2001-10-03 Tanox, Inc. Anti-c2/c2a inhibitors of complement activation
AU2001282857A1 (en) 2000-06-21 2002-01-02 Zymogenetics Inc. Peptide and polypeptide inhibitors of complement c1s
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
GB0105924D0 (en) 2001-03-09 2001-04-25 Microscience Ltd Promoter
US20030049260A1 (en) 2001-07-26 2003-03-13 Leonard Bell Method of improving cognitive function
WO2003042361A2 (en) 2001-11-09 2003-05-22 Government Of The United States Of America, Department Of Health And Human Services Production of adeno-associated virus in insect cells
NZ533692A (en) 2002-01-11 2006-09-29 Gtc Biotherapeutics Inc Improved methods for the fusion and activation of reconstructed embryos for use in nuclear transfer procedures in non-human mammals
US20080206242A1 (en) 2002-03-01 2008-08-28 Xencor, Inc. Method of treatment of th2-mediated conditions using optimized anti-cd30 antibodies
US7657380B2 (en) 2003-12-04 2010-02-02 Xencor, Inc. Methods of generating variant antibodies with increased host string content
SE0202880D0 (sv) 2002-07-26 2002-09-30 Wieslab Ab Complement system deficiency assay
US7666627B2 (en) 2002-08-08 2010-02-23 Targetex Kft. Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
NZ538384A (en) 2002-09-06 2009-04-30 Alexion Pharma Inc Treatment for asthma using a compound which binds to or otherwise blocks the generation and/or activity of one or more complement components reptors, such as, C5a receptors
US7361339B2 (en) 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
US9715692B1 (en) 2003-04-11 2017-07-25 Facebook, Inc. System for managing bids for pay-per-click search engines
US8329169B2 (en) 2003-05-15 2012-12-11 Genentech, Inc. Methods and compositions for the prevention and treatment of sepsis
WO2005014849A2 (en) 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
US7482376B2 (en) 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
WO2005025509A2 (en) 2003-09-11 2005-03-24 Board Of Regents, The University Of Texas System Methods and materials for treating autoimmune diseases and conditions
US8501705B2 (en) 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
EP2311945A1 (en) 2003-10-14 2011-04-20 Chugai Seiyaku Kabushiki Kaisha Bispecific antibodies substituting for functional proteins
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
JP4633788B2 (ja) * 2004-04-13 2011-02-16 エフ．ホフマン−ラ ロシュ アーゲー 抗ｐ−セレクチン抗体
US20060018896A1 (en) 2004-06-10 2006-01-26 University Of Leicester Methods for treating conditions associated with lectin-dependent complement activation
EP2465534B1 (en) 2004-06-10 2017-03-29 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
CA2587617C (en) 2004-11-12 2011-02-01 Xencor, Inc. Fc variants with altered binding to fcrn
WO2006063150A2 (en) 2004-12-08 2006-06-15 Immunomedics, Inc. Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
MX2007011293A (es) 2005-03-16 2008-03-18 Johnson & Johnson Tiofenosulfoximinas novedosas para el tratamiento de enfermedades y condiciones mediadas por el complemento.
ES2523666T3 (es) 2005-05-31 2014-11-28 Board Of Regents, The University Of Texas System Anticuerpos IgG1 con la parte Fc mutada para el aumento de unión al receptor FcRn y usos de los mismos
EP2529746A1 (en) 2005-06-06 2012-12-05 Girish J. Kotwal Methods for treatment or prophylaxis of reperfusion injury
JP5193600B2 (ja) 2005-07-05 2013-05-08 株式会社カネカ メタクリル系樹脂組成物
EP1937720B1 (en) 2005-08-18 2014-04-09 Ramot at Tel-Aviv University Ltd. Single chain antibodies against beta-amyloid peptide
EP2433642B1 (en) 2005-10-21 2016-12-07 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
US9480658B2 (en) 2005-12-09 2016-11-01 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
WO2007070375A2 (en) 2005-12-09 2007-06-21 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
KR101508668B1 (ko) 2005-12-21 2015-04-06 파밍 인텔렉츄얼 프라퍼티 비.브이. 허혈-재관류 손상의 예방을 위한 ｃ１ 억제제의 용도
FR2897868B1 (fr) * 2006-02-24 2012-08-31 Lab Francais Du Fractionnement Anticorps anti-idiotypiques neutralisant l'activite inhibitrice d'un anticorps inhibiteur dirige contre le domaine c1 du facteur viii.
DK1991275T3 (en) 2006-03-08 2014-12-08 Archemix Llc Complement aptamers AND ANTI-C5 AGENTS FOR USE IN THE TREATMENT OF EYE DISEASES
WO2008060645A2 (en) 2006-03-21 2008-05-22 Genentech, Inc. Combinatorial therapy involving alpha5beta1 antagonists
ES2785223T3 (es) 2006-06-21 2020-10-06 Uniqure Ip Bv Células de insecto para la producción de vectores de AAV
CA2662480C (en) 2006-09-05 2016-11-08 Alexion Pharmaceuticals, Inc. Methods and compositions for the treatment of antibody mediated neuropathies
CA3154415A1 (en) 2006-10-10 2008-04-17 Regenesance B.V. Anti-sense oligonucleotide for use in facilitating axonal regeneration
US7858752B2 (en) 2006-12-05 2010-12-28 Abbott Laboratories Recombinant antibodies against hepatitis C virus and methods of obtaining and using same
CN101679219B (zh) 2006-12-19 2014-08-13 港大科桥有限公司 合成离子通道
HUE026001T2 (en) 2007-02-05 2016-04-28 Apellis Pharmaceuticals Inc Compstatin analogues for use in the treatment of the inflammatory condition of the respiratory system
US8192742B2 (en) 2007-03-23 2012-06-05 NovelMed Therapeutics Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
JP5469600B2 (ja) 2007-07-16 2014-04-16 ジェネンテック， インコーポレイテッド 抗ＣＤ７９ｂ抗体及びイムノコンジュゲートとその使用方法
ES2622107T3 (es) 2007-08-03 2017-07-05 Genentech, Inc. Antagonistas anti-FGF19 humanizados y métodos de uso de los mismos
US7788398B2 (en) * 2007-08-08 2010-08-31 Swarmcast, Inc. Media player plug-in installation techniques
DK2808343T3 (da) 2007-12-26 2019-08-19 Xencor Inc Fc-varianter med ændret binding til FcRn
US20110190221A1 (en) 2008-03-28 2011-08-04 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
WO2009132058A2 (en) 2008-04-25 2009-10-29 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
US20110081347A1 (en) 2008-06-04 2011-04-07 Macrogenics, Inc. Antibodies with Altered Binding to FcRn and Methods of Using Same
US20090324585A1 (en) 2008-06-12 2009-12-31 The Trustees of the Leland Standford Junior University Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
HUE026179T2 (en) 2008-08-05 2016-05-30 Novartis Ag Preparations and methods for antibodies against complement C5 protein
WO2010047830A2 (en) 2008-10-24 2010-04-29 The Scripps Research Institute Agents for hcv treatment
BRPI0921237A2 (pt) 2008-11-10 2015-09-22 Alexion Pharma Inc métodos e composições para o tratamento de distúrbios associados ao complemento
US10338080B2 (en) 2008-12-01 2019-07-02 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detection of complement fixing antibodies
EP3153524B1 (en) * 2008-12-03 2025-04-23 Genmab A/S Antibody variants having modifications in the constant region
US8401799B2 (en) 2008-12-05 2013-03-19 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
US20100291106A1 (en) 2009-05-06 2010-11-18 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
CN102597005A (zh) 2009-06-23 2012-07-18 阿雷克森制药公司 与补体蛋白质结合的双特异性抗体
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
SI2488203T1 (sl) 2009-10-16 2017-07-31 Omeros Corporation Metode za zdravljenje diseminirane intravaskularne koagulacije z inhibiranjem aktivacije masp-2 odvisnega komplementa
JP5851391B2 (ja) 2010-02-16 2016-02-03 国立大学法人京都工芸繊維大学 抗体固定化担体、抗体固定化担体の製造方法および当該抗体固定化担体の利用
MX2012010116A (es) 2010-03-01 2013-02-26 Alexion Pharma Inc Metodos y composiciones para el tratamiento de la enfermedad de degos.
CA2833908C (en) 2010-04-23 2021-02-09 University Of Massachusetts Cns targeting aav vectors and methods of use thereof
BR112012027900A2 (pt) 2010-04-30 2020-05-12 Alexion Pharmaceuticals, Inc. Anticorpos anti-c5a e métodos para usar os anticorpos
KR20130135028A (ko) 2010-05-17 2013-12-10 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 동물로부터 단일클론 항체의 고속 분리
CA2803588A1 (en) 2010-06-22 2011-12-29 The Regents Of The University Of Colorado, A Body Corporate Antibodies to the c3d fragment of complement component 3
US9421240B2 (en) 2010-06-22 2016-08-23 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
TWI560199B (en) 2010-08-31 2016-12-01 Sanofi Sa Peptide or peptide complex binding to α2 integrin and methods and uses involving the same
TW201241008A (en) 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
US8865164B2 (en) 2010-11-02 2014-10-21 Kypha, Inc. Detecting complement activation
SI3461847T1 (sl) 2010-12-06 2021-03-31 Seagen Inc. Humanizirana protitelesa proti LIV-1 in njihova uporaba pri zdravljenju raka
MX2013007392A (es) 2010-12-22 2013-11-01 Cephalon Australia Pty Ltd Anticuerpo modificado con vida media mejorada.
KR101870915B1 (ko) 2011-04-08 2018-06-25 유니버시티 오브 레스터 Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
HUE049154T2 (hu) 2011-05-04 2020-09-28 Omeros Corp Készítmények a MASP-2-függõ komplement-aktiválás gátlására
US9289467B2 (en) 2011-08-10 2016-03-22 Case Western Reserve University Compositions and methods for treating bone conditions
DK2793935T3 (en) 2011-12-22 2016-09-05 Csl Behring Gmbh Use of C1 inhibitor in the treatment of secondary edema in the central nervous system.
JP6081699B2 (ja) 2011-12-28 2017-02-15 雅史 溝上 Ｉｌ−２８ｂの分析方法
KR102041412B1 (ko) 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
EP3722320A3 (en) * 2012-10-25 2020-12-30 Bioverativ USA Inc. Anti-complement c1s antibodies and uses thereof
PT2914291T (pt) 2012-11-02 2022-05-05 Bioverativ Usa Inc Anticorpos anti-complemento c1s e suas utilizações
BR112015018438A2 (pt) * 2013-01-31 2017-07-18 Seoul Nat Univ R&Db Foundation anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento
US20140294812A1 (en) 2013-03-15 2014-10-02 Xencor, Inc. Fc variants that improve fcrn binding and/or increase antibody half-life
WO2014186599A2 (en) 2013-05-15 2014-11-20 Annexon, Inc. Anti-complement factor c1s antibodies and uses thereof
ES2904709T3 (es) * 2013-05-23 2022-04-05 Broteio Pharma B V Moléculas de unión que se unen al factor C2B del complemento humano y usos de las mismas
BR112016000106B1 (pt) * 2013-07-09 2023-11-21 Annexon, Inc. Anticorpos anti-c1q e usos dos mesmos, célula de hibridoma, composição farmacêutica e métodos de detecção de sinapses em uma amostra biológica referências cruzadas a pedidos relacionados
WO2015084999A1 (en) 2013-12-06 2015-06-11 True North Therapeutics, Inc. Complement component biomarker assays
WO2016059512A1 (en) 2014-10-18 2016-04-21 Pfizer Inc. Anti-il-7r antibody compositions
HRP20230093T1 (hr) * 2015-04-06 2023-03-31 Bioverativ Usa Inc. Humanizirana anti-c1s protutijela i postupci njihove primjene
AU2016282782A1 (en) 2015-06-26 2018-01-18 Bioverativ Usa Inc. Methods of treating autoimmune and alloimmune disorders
CN116554320A (zh) 2016-10-12 2023-08-08 美国比奥维拉迪维股份有限公司 抗C1s抗体及其使用方法
SG11201907583TA (en) 2017-03-14 2019-09-27 Bioverativ Usa Inc Methods for treating complement-mediated diseases and disorders
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
JP7333789B2 (ja) 2018-04-13 2023-08-25 中外製薬株式会社 抗補体成分抗体および使用方法
WO2020081408A1 (en) 2018-10-18 2020-04-23 Merck Sharp & Dohme Corp. Formulations of anti-rsv antibodies and methods of use thereof
CA3187866A1 (en) 2020-08-06 2022-02-10 Jaime Morales ARIAS Inflammatory cytokines and fatigue in subject with a complement mediated disease
TW202304508A (zh) 2021-03-31 2023-02-01 美商百歐維拉提夫美國公司 減少冷凝集素疾病患者之手術相關溶血
IL317666A (en) 2022-06-15 2025-02-01 Bioverativ Usa Inc Anti-complement formulation for C1S antibody
AU2023286689A1 (en) 2022-06-24 2025-02-06 Bioverativ Usa Inc. Methods for treating complement-mediated diseases

Also Published As

Publication number Publication date
DK3525583T3 (da) 2025-10-27
MX2024008202A (es) 2024-07-15
HRP20251304T1 (hr) 2025-12-05
AU2022205174A1 (en) 2022-09-29
JP7420864B2 (ja) 2024-01-23
AR110677A1 (es) 2019-04-24
BR112019007309A2 (pt) 2019-07-02
TWI846007B (zh) 2024-06-21
CL2019000975A1 (es) 2019-10-04
EP4652926A2 (en) 2025-11-26
EP3525583B8 (en) 2025-09-10
CO2019004741A2 (es) 2019-07-31
JP2020502996A (ja) 2020-01-30
AU2025267421A1 (en) 2025-12-04
TW202246327A (zh) 2022-12-01
US20240076363A1 (en) 2024-03-07
EP3525583A4 (en) 2020-06-10
KR20250171438A (ko) 2025-12-08
US12391750B2 (en) 2025-08-19
IL265957B2 (en) 2024-04-01
CN116554320A (zh) 2023-08-08
TWI773695B (zh) 2022-08-11
US20200048332A1 (en) 2020-02-13
CN110300520A (zh) 2019-10-01
PT3525583T (pt) 2025-10-22
CN110300520B (zh) 2022-10-04
JP2024038319A (ja) 2024-03-19
CR20190223A (es) 2019-08-21
IL265957B1 (en) 2023-12-01
AU2022205174B2 (en) 2025-08-14
ZA201902247B (en) 2024-07-31
TW201821437A (zh) 2018-06-16
EP3525583B1 (en) 2025-07-23
JP2022105114A (ja) 2022-07-12
KR20240025715A (ko) 2024-02-27
KR102891406B1 (ko) 2025-11-27
ECSP19033211A (es) 2019-07-31
TW202434298A (zh) 2024-09-01
MX2019004259A (es) 2019-09-27
EA201990884A1 (ru) 2019-10-31
KR20190082783A (ko) 2019-07-10
MY198182A (en) 2023-08-09
WO2018071676A1 (en) 2018-04-19
PE20191031A1 (es) 2019-08-05
IL308156A (en) 2023-12-01
ES3049257T3 (en) 2025-12-15
TN2019000109A1 (en) 2020-10-05
DOP2019000085A (es) 2019-07-31
AU2017341766A1 (en) 2019-05-23
EP3525583A1 (en) 2019-08-21
CA3040253A1 (en) 2018-04-19
KR102638884B1 (ko) 2024-02-22
NZ753111A (en) 2025-06-27
RS67326B1 (sr) 2025-11-28
JP7069138B2 (ja) 2022-05-17
PH12019500789A1 (en) 2019-07-29
SG11201903012RA (en) 2019-05-30
IL265957A (en) 2019-05-30
FI3525583T3 (fi) 2025-10-31

Similar Documents

Publication Publication Date Title
LT3618863T (lt) Anti-tigit antikūnai ir jų panaudojimo būdai
LT3601358T (lt) Anti-trem2 antikūnai ir jų naudojimo metodai
LT3295951T (lt) Anti-pvrig antikūnai ir naudojimo būdai
IL265800A (en) Anti-lag-3 antibodies and methods of using them
LT3525583T (lt) Anti-c1s antikūnai ir jų naudojimo būdai
ZA202003695B (en) Anti-neuropilin antigen-binding proteins and methods of use thereof
IL262095A (en) Anti-pacap antibodies and uses thereof
IL251970B (en) Anti-cd79b antibodies and methods of use
SG10201912879YA (en) Anti-sirp-alpha antibodies and methods of use thereof
IL263657A (en) Anti-c5 antibodies and methods of use
SG10201912563XA (en) Anti-tim-3 antibodies and methods of use thereof
PL3353210T3 (pl) Przeciwciała anty-TIGIT i sposoby stosowania
LT3383916T (lt) Antikūnai prieš cd73 ir jų panaudojimo būdai
KR20180084817A (ko) 항-siglec-9 항체 및 이의 이용 방법
LT3303396T (lt) Antikūnai prieš ox40 ir jų panaudojimo būdai
LT3618928T (lt) Anti-sortilino antikūnai ir jų panaudojimo būdai
LT3333191T (lt) Anti-c10orf54 antikūnai ir jų panaudojimas
LT3443009T (lt) Anti-tim-3 antikūnai ir kompozicijos
LT3280441T (lt) Anti-sortilino antikūnai ir jų naudojimo būdai
LT3353212T (lt) Optimizuoti anti-cd3 bispecifiniai antikūnai ir jų naudojimas
DK3215532T3 (da) Anti-TIM3-antistoffer og fremgangsmåder til anvendelse
LT3274370T (lt) Antikūnai prieš ceacam6 ir jų panaudojimas
PL3250610T3 (pl) Przeciwciała anty-FcRn i sposoby ich stosowania
LT3532499T (lt) Antikūnai prieš il-33 ir jų panaudojimas
LT3436022T (lt) Oksisteroliai ir jų panaudojimo būdai